Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. reports developments in molecular diagnostics, including its patented platform for designing molecular diagnostic tests and its Co-Dx PCR platform. Company news commonly covers clinical and regulatory disclosures, commercialization activity through CoSara and CoMira joint ventures, intellectual property and technology updates, and operating and financial results.
Recurring updates also include material agreements, governance matters, capital-structure actions, and securities-listing developments. The company’s public disclosures connect its diagnostic-test pipeline, platform development, and commercialization strategy with financing, shareholder approvals, and other corporate actions.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced its participation in the 89th Annual American Mosquito Control Association (AMCA) conference from February 28 to March 3, 2023, in Reno, Nevada. The event is a key networking opportunity for professionals in mosquito control, where Co-Diagnostics will showcase its vector control PCR products. After a year of growth in laboratory installations and reagent purchases, the Company aims to enhance its market presence. Attendees can visit Booth #107 to learn more about Co-Diagnostics' offerings, including its Vector Smart™ tests. For more details about the conference, visit the AMCA website.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced the start of clinical evaluations for its at-home and point-of-care Co-Dx PCR Home™ platform, including an initial COVID-19 test. These evaluations aim to support submissions for regulatory approvals from the FDA and other bodies. The platform utilizes patented Co-Primer™ technology, offering advanced diagnostics for infectious diseases. No specific timeline for completion has been provided due to required patient enrollment. CEO Dwight Egan emphasized the significance of this milestone, highlighting over two years of R&D and the potential global impact of this innovative diagnostic technology.
Co-Diagnostics, Inc. (Nasdaq: CODX) will host a booth at Medlab Middle East 2023, taking place from February 6-9 at the Dubai World Trade Centre. The event is expected to attract over 20,000 visitors and 700 exhibitors from 40+ countries, highlighting advancements in laboratory technology. This platform allows Co-Diagnostics to showcase its products, including the upcoming Co-Dx PCR Home™ platform, to international customers, particularly in the Middle East, a significant market for the company. Attendees can visit Booth Z1.F51 for more information and product insights.
Summary not available.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) is exhibiting at the 2023 Consumer Electronics Show in Las Vegas from January 5-8. The company will showcase its Co-Dx PCR at-home and point-of-care platform, which is undergoing clinical evaluations prior to FDA submission. Interested attendees can visit Booth #8063 in the North Hall. The Co-Dx PCR platform is currently not for sale and is pending FDA review. Co-Diagnostics specializes in molecular diagnostics technology, focusing on nucleic acid detection for various applications.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) will present at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022. The event takes place from November 29 to December 1, 2022, in New York City. CEO Dwight Egan and President Dr. Kirk Ririe will discuss recent advancements and the upcoming Co-Dx PCR diagnostic platform. The presentation will be available online at 11:30 AM Eastern Time on the day of the event. Additionally, one-on-one meetings for institutional investors will be coordinated with Company or Piper Sandler representatives.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announces its participation at the MEDICA 2022 trade fair in Düsseldorf, Germany, from November 15-17. This renowned event, the largest medical trade fair globally, attracts thousands of exhibitors from over 50 countries. Co-Dx aims to showcase its in vitro diagnostic products for COVID-19 and other infectious diseases, alongside its innovative CoPrimer™ technology. Attendees are encouraged to visit Booth 3D15 for more insights on the Company’s offerings, including the upcoming Co-Dx PCR Home platform.
Co-Diagnostics, Inc. (NASDAQ: CODX) reported third quarter 2022 results with revenue of $5.1 million, a significant drop from $30.1 million in the prior year, but a slight increase of 1.4% from Q2. Gross profit was $4.3 million (84.9% of revenue), while operating loss reached $6.5 million, contrasting with a $13.6 million profit last year. The net loss was $1.4 million, down from $11.5 million profit previously. The company repurchased 2.9 million shares at an average price of $3.61. Despite lower COVID-19 test demand, progress on the Co-Dx PCR Home platform is promising, with clinical trials expected soon.
Co-Diagnostics (Nasdaq-CM: CODX) has announced its participation at the Association for Molecular Pathology (AMP) annual expo in Phoenix, AZ, from November 1-5. The event is a key gathering for molecular diagnostics professionals. Visitors can explore Co-Diagnostics' pioneering CoPrimer™ PCR technology and infectious disease products at booth #712. The expo starts at 12 pm PT on November 3. For further details, registration information is available here.
Co-Diagnostics, Inc. (Nasdaq: CODX) has appointed Dr. Mark Poritz as the new Chief Scientific Officer. Dr. Poritz is a seasoned molecular biologist with over 30 years of experience in molecular diagnostics, notably at BioFire Diagnostics. He has previously led significant developments, including the FilmArray platform. His appointment comes with an emphasis on enhancing the accessibility of innovative diagnostic solutions. The company also expresses gratitude to outgoing CSO Dr. Jesse Montgomery for his contributions.